Teva- Pharmaceutical Industries Ltd chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share 13.45
Dividend & YieldN/A$ (N/A)
Beta 1.22
Market capitalization 11.29B
Operating cash flow 1.59B
ESG Scores unknown

Company description

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also manufactures and sells active pharmaceutical ingredients, as well as provides contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. In addition, it focuses on the central nervous system (CNS), pain, respiratory, and oncology areas. The company's products portfolio in the CNS field comprises Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; and AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; respiratory therapeutic area includes ProAir RespiClick, QVAR, ProAir Digihaler, AirDuo Digihaler, ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease; and oncology therapeutic field consists of Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

Sector: Healthcare - Industry: Drug Manufacturers—Specialty & Generic

Financial Ratios
Quick Ratio0.79
Working Capital0.27
Return On Equity0.04
Debt To Equity2.1
Fixed Asset Ratio0.2
Fixed Interest Cover3.46

Financial data

Financial Statements

Cashflow Statement 2019-12-31 2020-12-31 2021-12-31 2022-12-31
Change To Liabilities 643M -463M 764M 1.91B
Total Cashflows From Investing Activities 1.35B 863M 1.52B 656M
Net Borrowings -1.86B -1.88B -2.17B -1.37B
Total Cash From Financing Activities -1.93B -1.89B -2.17B -1.49B
Change To Operating Activities -1.42B -1.47B -2.27B -828M
Issuance Of Stock
Net Income -999M -3.99B 417M -2.35B
Change In Cash 193M 202M 21M 636M
Effect Of Exchange Rate 16M 8M -128M -123M
Total Cash From Operating Activities 748M 1.22B 798M 1.59B
Depreciation 1.72B 1.56B 1.33B 1.31B
Change To Account Receivables -394M -293M -574M 334M
Other Cashflows From Financing Activities -11M -5M -6M -118M
Change To Netincome 921M 5.84B 752M 1.38B
Capital Expenditures -525M -578M -562M -548M

Income Statement 2019-12-31 2020-12-31 2021-12-31 2022-12-31
Research Development 1.01B 997M 967M 838M
Income Before Tax -1.28B -4.27B 667M -3.04B
Net Income -999M -3.99B 417M -2.35B
Selling General Administrative 3.81B 3.67B 3.53B 3.44B
Gross Profit 7.54B 7.73B 7.59B 6.97B
Ebit 2.72B 3.06B 3.08B 2.66B
Operating Income 2.72B 3.06B 3.08B 2.66B
Interest Expense -822M -901M -891M -930M
Income Tax Expense -278M -168M 211M -638M
Total Revenue 16.89B 16.66B 15.88B 14.93B
Cost Of Revenue 9.35B 8.93B 8.28B 7.95B
Total Other Income ExpenseNet -4B -7.32B -2.41B -5.71B
Net Income From Continuing Ops -1B -4.1B 456M -2.41B
Net Income Applicable To Common Shares -999M -3.99B 417M -2.35B

Balance Sheet Statement 2019-12-31 2020-12-31 2021-12-31 2022-12-31
Total Liabilities 42.41B 39.58B 36.42B 35.31B
Total Stockholder Equity 13.97B 10.03B 10.28B 7.9B
Other Current Liabilities 2.93B 2.76B 2.53B 2.42B
Total Assets 57.47B 50.64B 47.67B 44.01B
Common Stock 56M 57M 57M 57M
Other Current Assets 521M 899M 986M 559M
Retained Earnings -6.96B -10.95B -10.53B -12.88B
Treasury Stock -6.44B -6.53B -6.81B -6.97B
Cash 1.98B 2.18B 2.17B 2.8B
Total Current Liabilities 13.67B 13.16B 11.03B 11.47B
Other Stockholder Equity -2.31B -2.4B -2.68B -2.84B
Property, Plant, and Equipment 6.95B 6.86B 6.48B 6.16B
Total Current Assets 13.46B 13.01B 12.57B 12.05B
Net Tangible Assets -22.11B -19.52B -17.23B -16.01B
Net Receivables 5.68B 4.58B 4.53B 3.7B
Accounts Payable 1.72B 1.76B 1.69B 1.89B


Insider Transactions

Here are the insider transactions of stock shares related to Teva- Pharmaceutical Industries Ltd:

Filer Name Transaction Text Ownership Date Filer Relation Shares
NO DATA

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to Teva- Pharmaceutical Industries Ltd. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on Teva- Pharmaceutical Industries Ltd

Here is the result of two systematic investment strategies applied to Teva- Pharmaceutical Industries Ltd. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on Teva- Pharmaceutical Industries Ltd

The following chart shows the equity curve of the two systematic investment strategies applied to Teva- Pharmaceutical Industries Ltd:

Teva- Pharmaceutical Industries Ltd automated entries

The systematic investment strategy that buys the first day of the month would give a performance of -20.85% on the backtest period.

Performance at glance

Performance

-20.85 %

Latent gain

-473.95 $

Invested capital

2272.9 $

Annualized return

-5.04 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on Teva- Pharmaceutical Industries Ltd

This is the result of two momentum investment strategies applied to Teva- Pharmaceutical Industries Ltd. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on Teva- Pharmaceutical Industries Ltd

The following chart shows all the entries opened by the momentum investment system on Teva- Pharmaceutical Industries Ltd:

Teva- Pharmaceutical Industries Ltd momentum entries
  • The first momentum investment strategy would give -20.51% of return on Teva- Pharmaceutical Industries Ltd. That represents -1281.87$ of latent gain with 6249.12$ of employed capital.
  • The second momentum investment strategy would give -23.68% of return on Teva- Pharmaceutical Industries Ltd. That represents -652.47$ of latent gain with 2755.72$ of employed capital.
Performance at glance (1Q Momentum)

Performance

-20.51 %

Latent gain

-1281.87 $

Invested capital

6249.12 $

Annualized return

-1.66 %
Performance at glance (2Q Momentum)

Performance

-23.68 %

Latent gain

-652.47 $

Invested capital

2755.72 $

Annualized return

-6.47 %

Momentum equity curve on Teva- Pharmaceutical Industries Ltd

The following chart shows the equity curve of the two momentum strategies applied to Teva- Pharmaceutical Industries Ltd:

Teva- Pharmaceutical Industries Ltd momentum equity

Note: the dividends potentially given by Teva- Pharmaceutical Industries Ltd are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Teva- Pharmaceutical Industries Ltd

The following chart shows the employed capital evolution of the two momentum strategies on Teva- Pharmaceutical Industries Ltd since the beginning:

Teva- Pharmaceutical Industries Ltd

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Buy the dip strategy result on Teva- Pharmaceutical Industries Ltd

Buy the dip entry openings on Teva- Pharmaceutical Industries Ltd

Teva- Pharmaceutical Industries Ltd

The performance achieved by the robo-advisor on Teva- Pharmaceutical Industries Ltd is -3.55%. That represents -44.53$ of latent gain with 1252.78$ of employed capital. The following chart shows Teva- Pharmaceutical Industries Ltd stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of Teva- Pharmaceutical Industries Ltd, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

-3.55 %

Latent gain

-44.53 $

Invested capital

1252.78 $

Annualized return

-1.66 %

Equity curve of the strategy applied to Teva- Pharmaceutical Industries Ltd

The following chart shows the result of the investment strategy applied to Teva- Pharmaceutical Industries Ltd:

Teva- Pharmaceutical Industries Ltd

Note: the dividends potentially given by Teva- Pharmaceutical Industries Ltd are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Teva- Pharmaceutical Industries Ltd

The following chart shows the employed capital evolution since the beginning of the investment strategy on Teva- Pharmaceutical Industries Ltd:

Teva- Pharmaceutical Industries Ltd

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on Teva- Pharmaceutical Industries Ltd

In this section, I will compare the three previous investment strategies applied to Teva- Pharmaceutical Industries Ltd.

Equity curve comparison on Teva- Pharmaceutical Industries Ltd

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

Teva- Pharmaceutical Industries Ltd investment strategy comparison

Employed capital comparison on Teva- Pharmaceutical Industries Ltd

Teva- Pharmaceutical Industries Ltd investment comparison

Performance comparison on Teva- Pharmaceutical Industries Ltd

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment -20.85% -473.95$ 2272.9$ -5.04%
Momentum 1 quarter -20.51% -1281.87$ 6249.12$ -5.26%
Momentum 2 quarters -23.68% -652.47$ 2755.72$ -6.47%
Non-directional -3.55% -44.53$ 1252.78$ -1.66%
Annualized return comparison

Automatic investment

-5.04 %

Momentum 1Q

-6.47 %

Momentum 2Q

-6.47 %

Non-directional

-1.66 %

Correlated stocks

Here are the most positively and negatively correlated stocks with Teva- Pharmaceutical Industries Ltd:

Note: The algorithm computes the probability of correlation between Teva- Pharmaceutical Industries Ltd and the other stocks. There may be false positives or some missing correlated stocks. If the price of Teva- Pharmaceutical Industries Ltd does not vary for 36 weeks, the correlation calculation result will be wrong.


Company information

Company name Teva- Pharmaceutical Industries Ltd
Country Israel
City Tel Aviv
Address 124 Dvora Hanevi’a Street
Phone 972 3 914 8213
Website www.tevapharm.com
FullTime employees 34004
Industry Drug Manufacturers—Specialty & Generic
Sector Healthcare
Exchange XNYS
Ticker TEVA
Market www.nyse.com

Teva- Pharmaceutical Industries Ltd ESG Scores

Environment scores

Environment ESG Factors Scores
Environment Score 0
Peer Environment Performance unknown
Environment Percentile unknown
Palm Oil unknown
Nuclear unknown
Fur Leather unknown
GMO unknown
Coal unknown
Pesticides unknown
Animal Testing unknown

Social scores

Social ESG Factors Scores
Social Score 0
Peer Social Performance unknown
Social Percentile unknown
Highest Controversy unknown
Peer Highest Controversy Performance unknown
Adult unknown
Gambling unknown
Alcoholic unknown
Tobacco unknown
Catholic unknown
Controversial Weapons unknown
Small Arms unknown
Military Contract unknown
Peer Count unknown

Related Controversy:


Governance scores

Governance ESG Factors Scores
Governance Score 0
Peer Governance Performance unknown
Governance Percentile unknown

ESG at glance
Total ESG Scores: unknown
Environment Score: 0
Social Score: 0
Governance Score: 0

ESG Performance: unknown

Peer Group: unknown

Peer Esg Score Performance: unknown

Rating Year: unknown

Rating Month: unknown

Max Age: unknown

Percentile: unknown